Link Pharma Chem Ltd.
Snapshot View

36.95 -0.20 ▼-0.5%

23 July 2021, 04:00:00 P.M.
Volume: 1,704

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website
Financial Indicators
Market Cap 16.45 Cr.
Earnings per share (EPS) 2.44 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 15.18 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 28.29 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.31 Calculated using Price: 37.05
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.44 Cr. 4,440,568 Shares
FaceValue 10
Company Profile

Link Pharma Chem, incorporated on December 28, 1984 is a manufacturer of thionyl chloride.

The company manufactures thionyl chloride and other inorganic chemical intermediates at its plants located in the Baroda and Ankleshwar districts of Gujarat with an installed capacity of 2,100 TPA. In FY08, the company received an international grant from United Nations Industrial Development Organization of Rs 7.7 million for phasing out a carbon tetra chloride product as raw material, which was implemented. The company plans to develop the acquired land in the Baroda district and has purchased a 10,800 sq. m. plot with RCC building of approximately 50,000 sq. ft. constructed area from DRT Ahmedabad for Rs 14 million for diversification projects.

Link Pharma Chem has, over the years, followed the best business practices. The company believes that good corporate governance is essential to achieve long-term corporate goals and to enhance stakeholders' value. In this pursuit, the company is committed to conducting business in accordance with the highest legal and ethical standard, superior product quality and services to its customers. All employees are bound by a code of conduct, which sets forth the company's policies on important issues, including relationship with customers, vendors and the government.

Business areas of the company:

The company manufactures thionyl chloride and other inorganic chemical intermediates at its plants located in the Baroda and Ankleshwar districts of Gujarat with an installed capacity of 2,100 TPA.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.54%
1 Week
-0.27%
1 Month
+8.36%
3 Month
+2.64%
6 Month
+63.13%
1 Year
+157.49%
2 Year
+229.91%
5 Year
+179.71%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 5.16 2.88 4.97 -23.07 6.83 2.58 12.34 6.53 8.71
Return on Capital Employed (%) 9.39 9.74 9.32 -8.74 9.83 9.26 15.38 10.31 12.87
Return on Assets (%) 2.18 1.20 2.01 -8.35 2.70 1.31 6.61 3.74 5.14

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 10 10 11 8 9 9 10 10 11
Non Curr. Liab. 4 5 6 8 1 2 3 3 4
Curr. Liab. 10 9 10 9 7 7 4 5 3
Minority Int.
Equity & Liab. 23 25 26 26 18 17 17 18 19
Non Curr. Assets 16 16 17 18 10 10 11 11 10
Curr. Assets 7 9 10 8 7 7 7 7 9
Misc. Exp. not W/O
Total Assets 23 25 26 26 18 17 17 18 19

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 18 16 24 18 12 16 24 25 25
Other Income 0 0 0 0 3 0 0 0 0
Total Income 18 17 24 18 15 16 24 25 26
Total Expenditure -16 -14 -21 -18 -13 -14 -21 -22 -23
PBIDT 2 2 3 -1 3 2 3 2 3
Interest -1 -1 -1 -1 -1 -1 -1 0 0
Depreciation 0 -1 -1 -1 -1 -1 -1 -1 -1
Taxation 0 0 0 1 0 0 0 0 0
Exceptional Items
PAT 1 0 1 -2 1 0 1 1 1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 3 -1 1 5 -4 2 4 1 3
Cash Fr. Inv. -2 -1 -1 -3 9 -1 -1 -1 -2
Cash Fr. Finan. -2 2 0 -1 -6 -1 -3 0 1
Net Change -1 0 0 1 -1 0 0 2
Cash & Cash Eqvt 0 0 0 1 0 0 0 0 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 51.49 51.49 51.49 51.49 51.49 51.49 51.49 51.49 51.49
Public 48.51 48.51 48.51 48.51 48.50 48.51 48.51 48.51 48.51
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 05 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Bhushan Joshi
Designation :- Company Secretary and Compliance Officer
Mon, 05 Jul 2021
Shareholding for the Period Ended June 30 2021
Link Pharma Chem Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Sat, 03 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended June 30 2021.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
NR 4 NR 4
Thu, 22 Jul 2021
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%